Respiratory Syncytial Virus Vaccines

01/01/2014 - "The corollary of this observation is that robust Th1 and/or low Th9, Th22, and TNFα inflammatory responses may be associated with efficient clearance of RSV infection and therefore desirable characteristics of an RSV vaccine. "
02/01/2013 - "No safe and effective RSV vaccine is available for the prevention of serious RSV infection. "
01/01/2022 - "A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection."
04/01/2023 - "Prior to the introduction of RSV vaccines, our study suggests that universal childhood PCV vaccination may result in a reduction in severe RSV infections in children and may be important for countries that are yet to consider PCV programs."
02/28/2023 - "Despite a number of RSV vaccine candidates in clinical trials, there are no existing disease-specific, self-reported measures that assess the symptoms and severity of RSV infection from the perspective of adult patients with acute RSV. "

09/01/2000 - "There is no safe and effective RSV vaccine to use in those infants who are at highest risk from the infection. "
06/15/2007 - "Thus, bRSV infection in cattle provides the ideal setting to evaluate the safety and efficacy of novel RSV vaccine strategies. "
02/01/2003 - "In the 20 years from 1960 to 1980, trials of several candidate RSV vaccines failed to attain the desired safety and protection against natural infection. "
05/01/2014 - "Infection severity increased in children in an immunization trial, hampering the over 4-decade-long quest for a successful RSV vaccine. "
01/11/2012 - "The development of RSV vaccine, however, has been hampered by the disastrous outcome of an earlier trial using an inactivated and parenterally administered RSV vaccine which did not confer protection but rather primed for enhanced disease upon natural infection. "

10/01/2023 - "More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus Vaccines for Adults Aged 60 Years and Older."
01/01/2020 - "These findings reveal a functionally distinct response to IFN-I by neonatal cDC1s that may leave young infants susceptible to viral infections, and provide a new target for exploration, in light of failed efforts to design neonatal RSV vaccines."
01/01/2014 - "Viral diseases: Zeroing in on RSV vaccine design."
08/01/2004 - "Vaccines for neonatal viral infections: towards a live respiratory syncytial virus vaccine:a study in risk."
01/01/2014 - "Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. "

01/01/2016 - "Models of human RSV pulmonary disease are needed to better understand RSV pathogenesis and to assess the efficacy of RSV vaccines. "
02/01/2015 - "These findings support a concept that recombinant influenza viruses carrying the RSV G conserved-domain can be developed as a promising RSV vaccine candidate without pulmonary disease. "
02/19/2013 - "Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells."
12/01/1993 - "Clearly, children with underlying cardiac or pulmonary disease would benefit from an RSV vaccine. "
07/01/1998 - "PFP-2 appears to be a promising vaccine for the elderly and for RSV-seropositive children with underlying pulmonary disease, whereas live cold-passaged (cp), temperature-sensitive (ts) RSV vaccines (denoted cpts vaccines) would most probably be useful in young infants. "

01/01/2021 - "We discuss the challenges for RSV vaccine trials and influenza immunisation campaigns, and highlight the considerable research opportunities that have arisen with the SARS-CoV-2 pandemic. "
01/01/2021 - "These costs can be used as a basis for planning treatment and preventive strategies, including cost-effectiveness studies for influenza and, in future, RSV vaccines."
01/01/2020 - "In this study of an adjuvanted RSV vaccine, we evaluated an RSV disease endpoint using a patient-reported outcome instrument (the inFLUenza Patient-Reported Outcome instrument [FLU-PRO]) and molecular testing for virologic confirmation. "
01/01/2017 - "Our study shows a substantial excess mortality associated with influenza and RSV in Western Kenya, especially among children <5 years and older persons with TB, supporting recommendations for influenza vaccination and efforts to develop RSV vaccines."
12/12/2023 - "Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future."